Clinical & Laboratory Haematology

Texto completo: acesso restrito. p. 29–34 Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-01-14T14:54:10Z No. of bitstreams: 1 M. De Souza Gonçalves.pdf: 180756 bytes, checksum: 6cc9ee5e35c50e2b235bb71f10a968d5 (MD5) Made available in DSpace on 2014-01-14T14:54:10Z (GMT). No. of bitstreams: 1 M. De Souza Gonçalves.pdf: 180756 bytes, checksum: 6cc9ee5e35c50e2b235bb71f10a968d5 (MD5) Previous issue date: 2003 α-Thalassemia is a synthesis hemoglobinopathy with a worldwide distribution. α-thalassemia-23.7kb (α-Thal23.7kb) was investigated by PCR and standard hematologic analysis techniques in 106 pregnant women – 53 heterozygous for hemoglobin (Hb) A and C (AC) and 53 homozygous for the normal Hb A (AA) with similar ages and race ancestry. Eleven (21%) of AC women were α-Thal23.7kb heterozygous and 1 (2%) was homozygous, while 12 AA women (23%) were heterozygous. In the AA group, the MCV differed among those with normal α genes and those with α-Thal23.7kb (P = 0.031). Statistical analysis of AC group patients with normal α genes and α-Thal23.7kb carriers showed differences in MCV (P = 0.001); MCH (P = 0.003) and Hb C concentrations (P = 0.011). Analysis of AA and AC group patients with normal α genes showed differences in RBC (P = 0.033), Hb concentration (P = 0.003) and MCHC (P < 0.0001). There were no statistically significant differences for any hematologic parameters between AC and AA group patients with the α-Thal23.7kb genotype. The AC α-Thal23.7kb homozygous women had low hematologic parameters. Serum ferritin levels were normal among the groups studied. These results emphasize the importance of diagnosis and follow-up of patients with hemoglobinopathy carriers during pregnancy in order to administer adequate therapy and avoid further complications for mothers and newborns.